Longeveron hires financial advisor to explore strategic options

Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company based in Miami, has retained Lucid Capital Markets, LLC as its financial advisor to explore potential strategic opportunities, including a possible business combination, according to a company statement.

The company did not disclose the terms of the engagement or provide a timeline for any potential transaction. Longeveron noted that the exploration of strategic options may not result in any definitive transaction.

Longeveron's lead investigational product is laromestrocel (Lomecel-B), a mesenchymal stem cell therapy derived from bone marrow of adult donors. The therapy is being developed for conditions including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease (AD). The U.S. Food and Drug Administration has granted the product five designations across those two programs.

You May Also Be Interested In

• X4 Pharmaceuticals targets 2028 data readout for neutropenia drug
• Seer rejects acquisition bids, will stay independent public company
• Republic Services board approves $5 billion share repurchase program